Related Experiment Video
Updated: Jul 4, 2026
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 12, 2013
Assay development and screening of inhibitors targeting the SARS-CoV-2 2'-O-methyltransferase NSP16
Mengtong Cao1, Carl W Trieshmann1, Subodh Kumar Samrat2
1Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, United States.
Abstract:
The coronavirus disease-2019 (COVID-19) pandemic, etiologically caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has profoundly impacted the global health. While vaccines have been developed, they have shown limited efficacy in treating patients already under infection or preventing infection with emerging SARS-CoV-2 variants. The nonstructural protein 16 (NSP16), with the assistance of the nonstructural protein 10 (NSP10), is responsible for forming the Cap-1 structure, which is critical for viral replication and immune evasion through the 5'-capping of viral mRNA. As a result, NSP16/NSP10 has emerged as a promising target for antiviral treatment of coronaviruses. In this study, we aimed to discover small molecule inhibitors of NSP16/NSP10 by leveraging recent structural insights and combined tools of virtual and experimental screenings. We designed a simple scintillation proximity assay to enable biochemical testing for NSP16/NSP10 enzymatic activity and applied it to screen inhibitors from candidate hit compounds that are derived from molecular docking-based virtual screenings. We identified potential hits that inhibit the NSP16 activity with cellular efficacy. Together with structural analysis and chemotype categorization, this study lays the groundwork for novel antiviral therapeutics development against SARS-CoV-2 and related coronaviruses.
Insights
Researchers identified novel small molecule inhibitors targeting the SARS-CoV-2 NSP16/NSP10 enzyme complex, crucial for viral replication and immune evasion. These findings pave the way for developing new antiviral therapies against COVID-19 and related coronaviruses.
Area of Science:
- Virology
- Drug Discovery
- Biochemistry
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, necessitates new therapeutic strategies beyond vaccines.
- The viral NSP16/NSP10 complex is essential for SARS-CoV-2 replication and immune evasion by mediating mRNA 5'-capping.
- NSP16/NSP10 represents a promising target for developing novel antiviral treatments.
Purpose of the Study:
- To discover small molecule inhibitors targeting the SARS-CoV-2 NSP16/NSP10 enzyme complex.
- To utilize structural insights and combined virtual and experimental screening methods.
- To lay the groundwork for developing new antiviral therapeutics.
Main Methods:
- Employed molecular docking for virtual screening to identify candidate compounds.
- Developed a scintillation proximity assay for biochemical testing of NSP16/NSP10 enzymatic activity.
- Screened hit compounds from virtual screening using the developed assay.
Main Results:
- Identified potential small molecule inhibitors that effectively inhibit NSP16 activity.
- Confirmed cellular efficacy of the identified inhibitor candidates.
- Performed structural analysis and chemotype categorization of the hits.
Conclusions:
- The study successfully identified novel inhibitors of the SARS-CoV-2 NSP16/NSP10 complex.
- These inhibitors demonstrate potential for therapeutic development against SARS-CoV-2.
- The findings provide a foundation for future antiviral drug discovery efforts for coronaviruses.
